Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591502 | 0.90 | KMT2A (0.47) | KMT2AP2RX7LMNAALDH1A1KDM4E | |
| SCHEMBL1591354 | 0.89 | KCNQ2 (0.47) | P2RX7RAB9APARP14ALDH1A1NPC1 | |
| SCHEMBL1590600 | 0.89 | P2RX7 (0.44) | KMT2AP2RX7LMNAALDH1A1KDM4E | |
| SCHEMBL1591055 | 0.86 | LMNA (0.51) | KMT2AP2RX7LMNAALDH1A1KDM4E | |
| SCHEMBL1591062 | 0.85 | TSHR (0.47) | KMT2AP2RX7LMNAALDH1A1MEN1 | |
| SCHEMBL1591136 | 0.84 | P2RX7 (0.42) | P2RX7MAPT | |
| SCHEMBL1589957 | 0.83 | P2RX7 (0.47) | P2RX7RAB9APARP14ALDH1A1NPC1 | |
| SCHEMBL1589719 | 0.83 | TP53 (0.44) | KMT2AP2RX7RAB9AALDH1A1NPC1 | |
| SCHEMBL1590635 | 0.83 | P2RX7 (0.43) | P2RX7LMNAALDH1A1KDM4EHPGD | |
| SCHEMBL1590869 | 0.83 | PARP14 (0.44) | KMT2AP2RX7PARP14ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | claimed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | KMT2A 4614/4885P2RX7 1/4885LMNA 1911/4885 |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | KMT2A 4614/4885P2RX7 1/4885LMNA 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.